{"id":"https://openalex.org/W4401009042","doi":"https://doi.org/10.1016/j.iotech.2024.100725","title":"A novel anti-FGFR1 monoclonal antibody OM-RCA-01 exhibits potent antitumor activity and enhances the efficacy of immune checkpoint inhibitors in lung cancer models","display_name":"A novel anti-FGFR1 monoclonal antibody OM-RCA-01 exhibits potent antitumor activity and enhances the efficacy of immune checkpoint inhibitors in lung cancer models","publication_year":2024,"publication_date":"2024-07-26","ids":{"openalex":"https://openalex.org/W4401009042","doi":"https://doi.org/10.1016/j.iotech.2024.100725","pmid":"https://pubmed.ncbi.nlm.nih.gov/39290712","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/11403241"},"language":"en","primary_location":{"id":"doi:10.1016/j.iotech.2024.100725","doi":"https://doi.org/10.1016/j.iotech.2024.100725","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.iotech.2024.100725","pdf_url":"http://www.esmoiotech.org/article/S2590018824000224/pdf","source":{"id":"https://openalex.org/S4210240197","display_name":"Immuno-Oncology Technology","issn_l":"2590-0188","issn":["2590-0188"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","norway-1","poland-20"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Immuno-Oncology and Technology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://www.esmoiotech.org/article/S2590018824000224/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5070988170","display_name":"Ilya V. Tsimafeyeu","orcid":"https://orcid.org/0000-0002-7357-0392","observed_orcids":["https://orcid.org/0000-0002-7357-0392"]},"institutions":[{"id":"https://openalex.org/I4405267011","display_name":"Kidney Cancer Research Bureau","ror":"https://ror.org/00th63n98","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4405267011"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"I. Tsimafeyeu","raw_affiliation_strings":["Bureau for Cancer Research - BUCARE, New York"],"raw_orcid":"https://orcid.org/0000-0002-7357-0392","affiliations":[{"raw_affiliation_string":"Bureau for Cancer Research - BUCARE, New York","institution_ids":["https://openalex.org/I4405267011"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047243753","display_name":"Peter B. Makhov","orcid":"https://orcid.org/0000-0002-8257-4782","observed_orcids":["https://orcid.org/0000-0002-8257-4782"]},"institutions":[{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P. Makhov","raw_affiliation_strings":["Program in Cancer Signaling and Microenvironment, Fox Chase Cancer Center, Philadelphia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Program in Cancer Signaling and Microenvironment, Fox Chase Cancer Center, Philadelphia","institution_ids":["https://openalex.org/I1289437631"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078389534","display_name":"Dmitriy Ovcharenko","orcid":"https://orcid.org/0000-0003-1271-1099","observed_orcids":["https://orcid.org/0000-0003-1271-1099"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Ovcharenko","raw_affiliation_strings":["Altogen Labs, Austin, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Altogen Labs, Austin, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002512182","display_name":"Jonathan D. Smith","orcid":"https://orcid.org/0000-0002-0415-386X","observed_orcids":["https://orcid.org/0000-0002-0415-386X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Smith","raw_affiliation_strings":["Altogen Labs, Austin, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Altogen Labs, Austin, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069967200","display_name":"Yulia Khochenkova","orcid":"https://orcid.org/0000-0001-8392-5495","observed_orcids":["https://orcid.org/0000-0001-8392-5495"]},"institutions":[{"id":"https://openalex.org/I4210090957","display_name":"Russian Cancer Research Center NN Blokhin","ror":"https://ror.org/00ab9fg88","country_code":"RU","type":"facility","lineage":["https://openalex.org/I4210090957"]}],"countries":["RU"],"is_corresponding":false,"raw_author_name":"Y. Khochenkova","raw_affiliation_strings":["N.N. Blokhin National Medical Research Center of Oncology, Moscow"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"N.N. Blokhin National Medical Research Center of Oncology, Moscow","institution_ids":["https://openalex.org/I4210090957"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036714787","display_name":"Anna Sergeevna Olshanskaya","orcid":"https://orcid.org/0000-0003-0389-564X","observed_orcids":["https://orcid.org/0000-0003-0389-564X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Olshanskaya","raw_affiliation_strings":["Clinical Oncology Hospital No. 1, Moscow"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Oncology Hospital No. 1, Moscow","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5047528103","display_name":"Dmitry A. Khochenkov","orcid":"https://orcid.org/0000-0002-5694-3492","observed_orcids":["https://orcid.org/0000-0002-5694-3492"]},"institutions":[{"id":"https://openalex.org/I3129553732","display_name":"Togliatti State University","ror":"https://ror.org/03e2ja558","country_code":"RU","type":"education","lineage":["https://openalex.org/I3129553732"]},{"id":"https://openalex.org/I4210090957","display_name":"Russian Cancer Research Center NN Blokhin","ror":"https://ror.org/00ab9fg88","country_code":"RU","type":"facility","lineage":["https://openalex.org/I4210090957"]}],"countries":["RU"],"is_corresponding":false,"raw_author_name":"D. Khochenkov","raw_affiliation_strings":["Center for Medicinal Chemistry, Togliatti State University, Togliatti, Russia","N.N. Blokhin National Medical Research Center of Oncology, Moscow"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Medicinal Chemistry, Togliatti State University, Togliatti, Russia","institution_ids":["https://openalex.org/I3129553732"]},{"raw_affiliation_string":"N.N. Blokhin National Medical Research Center of Oncology, Moscow","institution_ids":["https://openalex.org/I4210090957"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5070988170"],"corresponding_institution_ids":["https://openalex.org/I4405267011"],"apc_list":{"value":3170,"currency":"USD","value_usd":3170},"apc_paid":{"value":3170,"currency":"USD","value_usd":3170},"fwci":0.7784,"has_fulltext":true,"cited_by_count":7,"citation_normalized_percentile":{"value":0.64049804,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"23","issue":null,"first_page":"100725","last_page":"100725"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12287","display_name":"Fibroblast Growth Factor Research","score":0.5435000061988831,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12287","display_name":"Fibroblast Growth Factor Research","score":0.5435000061988831,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.4219000041484833,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.02280000038444996,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/fgfr1","display_name":"FGFR1","score":0.8650000095367432},{"id":"https://openalex.org/keywords/lung-cancer","display_name":"lung cancer","score":0.9860000014305115},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9520000219345093},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.9340000152587891},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":1.0},{"id":"https://openalex.org/keywords/pd-l1","display_name":"PD-L1","score":0.7400000095367432},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.7360000014305115},{"id":"https://openalex.org/keywords/tumor-growth-inhibition","display_name":"tumor growth inhibition","score":0.6499999761581421},{"id":"https://openalex.org/keywords/interferon-gamma","display_name":"interferon-gamma","score":0.6150000095367432},{"id":"https://openalex.org/keywords/interleukin-2","display_name":"interleukin-2","score":0.9850000143051147},{"id":"https://openalex.org/keywords/humanized-antibody","display_name":"humanized monoclonal antibody","score":0.5210000276565552},{"id":"https://openalex.org/keywords/patient-derived-xenografts","display_name":"patient-derived xenografts","score":0.6930000185966492}],"concepts":[{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.7032593488693237},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.6611425876617432},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.588499128818512},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.5172908306121826},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.4447958171367645},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.3896626830101013},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3348294496536255},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3259837031364441},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.26842814683914185},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.2257610261440277},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2221599519252777},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.1499975621700287}],"mesh":[],"locations_count":4,"locations":[{"id":"doi:10.1016/j.iotech.2024.100725","doi":"https://doi.org/10.1016/j.iotech.2024.100725","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.iotech.2024.100725","pdf_url":"http://www.esmoiotech.org/article/S2590018824000224/pdf","source":{"id":"https://openalex.org/S4210240197","display_name":"Immuno-Oncology Technology","issn_l":"2590-0188","issn":["2590-0188"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","norway-1","poland-20"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Immuno-Oncology and Technology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:11403241","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11403241","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11403241/pdf/main.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Immunooncol Technol","raw_type":"Text"},{"id":"pmid:39290712","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/39290712","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Immuno-oncology technology","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:43c022b902de482aa5ac5965b28157dd","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/43c022b902de482aa5ac5965b28157dd","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Immuno-Oncology and Technology, Vol 23, Iss , Pp 100725- (2024)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1016/j.iotech.2024.100725","doi":"https://doi.org/10.1016/j.iotech.2024.100725","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.iotech.2024.100725","pdf_url":"http://www.esmoiotech.org/article/S2590018824000224/pdf","source":{"id":"https://openalex.org/S4210240197","display_name":"Immuno-Oncology Technology","issn_l":"2590-0188","issn":["2590-0188"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","norway-1","poland-20"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Immuno-Oncology and Technology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9922999739646912}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4401009042.pdf","grobid_xml":"https://content.openalex.org/works/W4401009042.grobid-xml"},"referenced_works_count":33,"referenced_works":["https://openalex.org/W1980448975","https://openalex.org/W2021197767","https://openalex.org/W2062789313","https://openalex.org/W2080073026","https://openalex.org/W2090103734","https://openalex.org/W2099609050","https://openalex.org/W2344431635","https://openalex.org/W2516271598","https://openalex.org/W2595713273","https://openalex.org/W2600903921","https://openalex.org/W2768987490","https://openalex.org/W2898174432","https://openalex.org/W3003058300","https://openalex.org/W3006479488","https://openalex.org/W3030606546","https://openalex.org/W3108059695","https://openalex.org/W3129646946","https://openalex.org/W3146829913","https://openalex.org/W3154805493","https://openalex.org/W4206494501","https://openalex.org/W4212900426","https://openalex.org/W4224082815","https://openalex.org/W4225464106","https://openalex.org/W4295836905","https://openalex.org/W4308595090","https://openalex.org/W4313897792","https://openalex.org/W4317355154","https://openalex.org/W4323975494","https://openalex.org/W4360951491","https://openalex.org/W4387938016","https://openalex.org/W4391096699","https://openalex.org/W4393096648","https://openalex.org/W6842891862"],"related_works":["https://openalex.org/W7167262257","https://openalex.org/W7167221975","https://openalex.org/W4282923998","https://openalex.org/W4295836905","https://openalex.org/W7162677255","https://openalex.org/W4411466111","https://openalex.org/W4387811022","https://openalex.org/W3212668399","https://openalex.org/W7122605223","https://openalex.org/W2955567541"],"abstract_inverted_index":{"Background":[0],"Fibroblast":[1],"growth":[2,125,202,215],"factor":[3],"receptor":[4,110],"1":[5],"(FGFR1)":[6],"plays":[7],"a":[8,69,120,132,155,196,254],"crucial":[9],"role":[10],"in":[11,33,54,68,84,87,113,123,131,147,158,174,191,220],"carcinogenesis.":[12],"Exploring":[13],"the":[14,17,80,148,161,167,221,259,271],"combination":[15,168,192,222],"of":[16,31,35,49,63,82,160,169,177,261,273],"novel":[18],"humanized":[19],"monoclonal":[20],"anti-FGFR1":[21,162,251],"antibody":[22,64,107,252],"OM-RCA-01":[23,59,77,117,172,194,225,242],"and":[24,41,86,96,143,150,171,180,206],"immunotherapy":[25,83],"was":[26,66,139],"intriguing":[27],"due":[28],"to":[29,37,119,127,269],"involvement":[30],"FGFR1":[32,50],"mechanisms":[34],"resistance":[36],"checkpoint":[38,255],"inhibitors.":[39],"Materials":[40],"methods":[42],"Lung":[43],"cancer":[44,71],"A549,":[45],"exhibiting":[46],"distinct":[47],"levels":[48,176],"expression,":[51],"were":[52,103],"cultured":[53],"basic":[55],"FGF":[56],"medium":[57],"with":[58,184,193,204,246,253],"supplementation.":[60],"The":[61,106,135,209,224],"efficacy":[62,81,260],"monotherapy":[65],"validated":[67],"lung":[70],"xenograft":[72,101,133],"study.":[73,134],"To":[74],"investigate":[75],"whether":[76],"could":[78],"enhance":[79,258],"vitro":[85,165],"vivo":[88,188],",":[89,166,189],"mixed":[90],"lymphocyte":[91],"reaction/Staphylococcal":[92],"enterotoxin":[93],"B":[94],"assays":[95],"FGFR1/programmed":[97],"death-ligand":[98],"1-positive":[99],"patient-derived":[100],"model":[102],"established.":[104],"Results":[105],"effectively":[108],"suppressed":[109],"phosphorylation,":[111],"resulting":[112],"inhibited":[114],"cell":[115],"proliferation.":[116],"led":[118],"substantial":[121],"delay":[122],"tumor":[124,137,201,214],"compared":[126,183,203],"non-specific":[128],"immunoglobulin":[129],"G":[130],"median":[136],"volume":[138],"1048.5":[140],"mm":[141,145],"3":[142,146],"2174":[144],"study":[149],"vehicle":[151,205],"groups,":[152],"respectively,":[153],"representing":[154],"twofold":[156],"difference":[157],"favor":[159],"antibody.":[163],"In":[164,187],"nivolumab":[170,185],"resulted":[173],"higher":[175,234],"interferon":[178],"gamma":[179],"interleukin-2":[181],"release":[182],"alone.":[186,208],"pembrolizumab":[190,207],"produced":[195],"greater":[197],"inhibitory":[198],"effect":[199],"on":[200],"curve":[210],"plateaued,":[211],"indicating":[212],"minimal":[213,247],"from":[216],"day":[217],"16":[218],"onwards":[219],"group.":[223],"demonstrated":[226],"no":[227],"toxicity,":[228],"even":[229],"at":[230],"therapeutic":[231],"doses":[232],"or":[233],"doses.":[235],"Conclusions":[236],"Our":[237],"preclinical":[238],"studies":[239,266],"demonstrate":[240],"that":[241],"exhibits":[243],"robust":[244],"activity":[245],"toxicity.":[248],"Combining":[249],"an":[250],"inhibitor":[256],"may":[257],"both":[262],"drugs.":[263],"However,":[264],"further":[265],"are":[267],"needed":[268],"elucidate":[270],"mechanism":[272],"this":[274],"interaction.":[275]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":1}],"updated_date":"2026-10-29T09:56:32.521200","created_date":"2024-07-27T00:00:00"}